Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Study results spark 13% drop in Perspective Therapeutics shares – Radiation levels in focus Shares of Perspective Therapeutics (NYSE AMERICAN: CATX) fell sharply, dropping over 13% to $11.49, after the latest data… byPallavi MadhirajuOctober 11, 2024